Sign in

CIK 0001778922

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

SpyGlass Pharma, Inc.

Sign in to watch
Ticker
SGP
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
833044245
Phone
+1 949-284-6904
Business address
15326 ALTON PARKWAY, IRVINE, CA, 92618
Former names
SpyGlassPharma, Inc., SpyGlass Ophthalmics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-02-09 Nielsen Kirk G. Director Conversion +359,255 3,145,619
2026-02-09 Nielsen Kirk G. Director Purchase +165,000 $16.00 $2.6M 3,310,619
2026-02-09 Nielsen Kirk G. Director Conversion · Series B Preferred Stock −9,689,922 0
2026-02-09 Nielsen Kirk G. Director Conversion · Series C-1 Preferred Stock −3,142,015 0
2026-02-09 Nielsen Kirk G. Director Conversion · Series C-2 Preferred Stock −3,142,015 0
2026-02-09 Nielsen Kirk G. Director Conversion · Series D Preferred Stock −2,059,573 0
2026-02-09 Vensana Capital I GP, LLC 10% owner Conversion +1,690,230 1,690,230
2026-02-09 Vensana Capital I GP, LLC 10% owner Conversion +548,067 2,238,297
2026-02-09 Vensana Capital I GP, LLC 10% owner Conversion +548,067 2,786,364
2026-02-09 Vensana Capital I GP, LLC 10% owner Conversion +359,255 3,145,619
2026-02-09 Vensana Capital I GP, LLC 10% owner Purchase +165,000 $16.00 $2.6M 3,310,619
2026-02-09 Vensana Capital I GP, LLC 10% owner Conversion · Series B Preferred Stock −9,689,922 0
2026-02-09 Vensana Capital I GP, LLC 10% owner Conversion · Series C-1 Preferred Stock −3,142,015 0
2026-02-09 Vensana Capital I GP, LLC 10% owner Conversion · Series C-2 Preferred Stock −3,142,015 0
2026-02-09 Vensana Capital I GP, LLC 10% owner Conversion · Series D Preferred Stock −2,059,573 0
2026-02-05 Khan Bilal Arshad Director Grant or award · Stock Option (right to buy) +13,700 13,700
2026-02-05 Pujara Chetan Pratap Chief R&D Officer Grant or award · Stock Option (right to buy) +105,000 105,000
2026-02-05 Dennewill James Robert Jr. Chief Operating Officer Grant or award · Stock Option (right to buy) +105,000 105,000
2026-02-05 Mooney Patrick H. Chief Executive Officer Grant or award · Stock Option (right to buy) +300,000 300,000
2026-02-05 Kahook Malik Y. See remarks Grant or award · Stock Option (right to buy) +105,000 105,000

Page 8 of 9 · 169 trades